1.22 USD
-0.03
2.40%
At close Jun 13, 4:00 PM EDT
1 day
-2.40%
5 days
-6.15%
1 month
-26.51%
3 months
-29.89%
6 months
-36.46%
Year to date
-37.44%
1 year
-30.68%
5 years
-46.49%
10 years
-82.52%
 

About: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Employees: 987

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,758% more call options, than puts

Call options by funds: $223K | Put options by funds: $12K

1.13% more ownership

Funds ownership: 54.48% [Q4 2024] → 55.61% (+1.13%) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 45

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

4% less funds holding

Funds holding: 132 [Q4 2024] → 127 (-5) [Q1 2025]

6% less capital invested

Capital invested by funds: $108M [Q4 2024] → $102M (-$5.97M) [Q1 2025]

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

Research analyst outlook

We haven’t received any recent analyst ratings for ARAY.

Financial journalist opinion

Based on 3 articles about ARAY published over the past 30 days

Neutral
PRNewsWire
1 week ago
Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
MADISON, Wis. , June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares").
Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
Positive
Zacks Investment Research
2 weeks ago
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
Neutral
PRNewsWire
2 weeks ago
Accuray to Participate in the Jefferies Global Healthcare Conference 2025
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.
Accuray to Participate in the Jefferies Global Healthcare Conference 2025
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Neutral
PRNewsWire
1 month ago
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the treatment of prostate cancer at multiple stages of the cancer journey.
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
Neutral
PRNewsWire
1 month ago
Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System
Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife ® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy.
Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System
Negative
Seeking Alpha
1 month ago
Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade)
Accuray has consistently struggled with execution, and now tariffs threaten to significantly impact the company's business in China - it's most promising growth driver. Recent Q3 results showed revenue growth but were overshadowed by weaker guidance and declining orders, particularly impacted by U.S.-China tariffs. The competition in China is intensifying, with local and global players ramping up efforts, challenging Accuray's ability to capitalize on a large market opportunity.
Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade)
Positive
Zacks Investment Research
1 month ago
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Neutral
Seeking Alpha
1 month ago
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
Accuray Incorporated (NASDAQ:ARAY ) Q3 2025 Earnings Call April 30, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marie Thibault - BTIG Jason Wittes - ROTH Capital Operator Good day and welcome to the Accuray Third Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.06 per share a year ago.
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™